Semaglutide salt forms: the single clearest gray-market signal
If a seller's semaglutide is a 'sodium' or 'acetate' salt, you have learned almost everything you need to know about that seller. Here is why.
Semaglutide base is the active ingredient in FDA-approved Wegovy and Ozempic. Semaglutide sodium and semaglutide acetate are different salt forms, and the FDA has stated they do not qualify for use in compounding under the exemptions that allow legitimate pharmacy compounding. Their presence is one of the most reliable markers that a seller is operating outside the regulated supply chain, alongside 'research use only' labeling and no-prescription sales.
- What a salt form is, in plain terms: Drug molecules are often paired with a counter-ion to change how they behave — solubility, stability, shelf life.
- Why salt forms mark the gray market: Legitimate compounding pharmacies work from active ingredients that meet the standards for compounding.
- What actually goes wrong: The concrete risks are potency and purity.
- How to check before you buy: Ask one direct question: is this semaglutide base, or a salt form such as semaglutide sodium or semaglutide acetate? A legitimate program dispensing t.
- What legitimate compounded semaglutide looks like: For contrast: a compliant program in 2026 dispenses base semaglutide, prepared by a U.S.-licensed 503A pharmacy or an FDA-registered 503B outsourcing .
What a salt form is, in plain terms
Drug molecules are often paired with a counter-ion to change how they behave — solubility, stability, shelf life. That paired version is a “salt form.” For many drugs, salt forms are legitimate and common. The issue with semaglutide is specific and legal, not merely chemical.
The FDA-approved products contain semaglutide in a particular form. The bulk material legitimately usable in compounding must be an appropriate form of the active ingredient. Semaglutide sodium and semaglutide acetate are variants that the agency has indicated do not meet the requirements — they are not the FDA-approved active ingredient, and they are not on the pathways that permit compounding a given substance.
| Attribute | Semaglutide base | Semaglutide sodium/acetate |
|---|---|---|
| In FDA-approved products | Yes (Wegovy, Ozempic) | No |
| Qualifies for compounding | Yes, appropriate form | FDA: does not qualify |
| Typical source | Licensed pharmacy chain | 'Research use only' gray market |
| Prescription | Required | Often none |
| Price signal | ~$100–$200/mo | $40–$80/mo offers |
Why salt forms mark the gray market
Legitimate compounding pharmacies work from active ingredients that meet the standards for compounding. Salt-form semaglutide is typically sourced from bulk API suppliers selling into the “research use only” gray market — the same channel that sells peptides without prescriptions under the fiction that the buyer is a laboratory. Salt forms are cheaper and easier to obtain, which is precisely why they show up in the lowest-priced offers.
So the presence of a salt form is a proxy for the whole operation. A seller using semaglutide sodium is very unlikely to also have the prescription requirement, the state-licensed dispensing pharmacy, and the sterile compounding standards that define the legitimate chain. One disqualifying fact usually travels with others.
What actually goes wrong
The concrete risks are potency and purity. A salt-form product may contain a different amount of active semaglutide than labeled, because the salt changes the mass-to-active ratio, and gray-market suppliers rarely provide verified assays. Under-dosing produces no effect; mis-dosing from an unlabeled concentration can produce hypoglycemia or severe GI effects.
The FDA had received hundreds of adverse-event reports linked to compounded semaglutide by early 2025, many involving dosing errors from multidose vials — some requiring hospitalization. Salt-form products from unverified sources sit at the sharp end of that data, because the buyer has no assurance of what the vial actually contains.
How to check before you buy
Ask one direct question: is this semaglutide base, or a salt form such as semaglutide sodium or semaglutide acetate? A legitimate program dispensing through a state-licensed pharmacy will answer clearly and will be dispensing base semaglutide against a prescription. A seller that dodges the question, or whose product page lists a salt form, has answered it for you.
Pair that with the rest of the verification chain: a real prescription after a clinician evaluation, a named dispensing pharmacy whose license you can verify on the state board lookup, and normal card payment rather than crypto or Zelle. Salt form plus any of those other red flags is not a bargain — it is a provenance warning.
What legitimate compounded semaglutide looks like
For contrast: a compliant program in 2026 dispenses base semaglutide, prepared by a U.S.-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility, against a prescription written after a provider evaluated you, with an individualized clinical rationale documented — because, as our compounding-rules guide explains, routine copies are no longer permitted post-shortage.
That program will name its pharmacy, state its formulation, and not rely on salt-form API. The price will sit at a real floor — roughly $100–$200 per month for legitimate compounded semaglutide — rather than the $40–$80 that signals gray-market salt material. Too-cheap is not a deal signal in this market; it is a sourcing signal.
There is also a documentation dimension worth understanding. A legitimate compounding pharmacy keeps records tying each batch to a specific active-ingredient source with a certificate of analysis, and a prescriber's individualized rationale ties each prescription to a patient. Salt-form gray-market material typically arrives with none of this chain of custody, which is why the salt form is not merely a chemistry footnote but a proxy for the absence of every safeguard that makes compounded medication reasonable to use in the first place.
If you suspect you have a salt-form product
Stop using it and photograph the labeling. Report to the FDA through MedWatch; the agency acts on consumer reports and has pulled products based on them. If you injected it and feel unwell, treat it as exposure to an unknown substance and seek care, bringing the vial.
Then fix the channel, not just the vial. The same few questions — base or salt, prescription or not, named pharmacy or not — turn the search that found a cheap seller into a screen the salt-form gray market cannot pass.
Frequently asked questions
Is semaglutide sodium the same drug as Ozempic?
No. Ozempic contains semaglutide base. Semaglutide sodium is a different salt form that the FDA has said does not qualify for compounding, and it is not the FDA-approved active ingredient.
Why do some sellers use salt forms?
They are cheaper and easier to source through the 'research use only' gray market that sells peptides without prescriptions. That cost advantage is why salt forms concentrate in the lowest-priced, least-regulated offers.
How do I know which form I'm getting?
Ask the program directly whether it dispenses semaglutide base or a salt form, and confirm a named, state-licensed dispensing pharmacy. A legitimate program answers clearly and dispenses base against a prescription.